Targeting Activin Signaling Activity in Combination with Immunomodulation to Alter Regulatory T cell-mediated Immune Regulation in order to Treat Cancer

Case ID:
C13915
Disclosure Date:
12/9/2015
Description:
Unmet Need
In the context of the tumor microenvironment, immunosuppressive regulatory T (Treg) cells can hinder anti-tumor immune responses and immunotherapies.  Agents that inhibit Treg function could greatly enhance the patients? own anti-tumor immune response, and enhance the effectiveness of existing immunotherapies.

Technology Overview
This technology includes a new target, Activin signaling, for cancer immunotherapy. 

Stage of Development 
Data in a melanoma, mouse xenograft model show that ablation of Activin signaling supresses tumor growth and enhances the effects of certain cell-based anti-tumor vaccines.  Currently work is underway to design a novel antibody-based therapy to inhibit Activin signaling. 

Related Technologies
C13353
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Targeting Activin Signaling Activity in Combination with Immunomodulation to Alter Regulatory T cell-mediated Immune Regulation in order to Treat Cancer PCT: Patent Cooperation Treaty PCT PCT/US2017/017354   2/10/2017     Pending
Inventors:
Category(s):
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum